| 000 | 01176 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250514030517.0 | ||
| 264 | 0 | _c20020412 | |
| 008 | 200204s 0 0 eng d | ||
| 040 |
_aNLM _beng _cNLM |
||
| 245 | 0 | 0 |
_aPancreas retransplantation. _h[electronic resource] |
| 260 |
_bTecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel _cDec 2001 |
||
| 300 |
_a33-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aBlue Cross Blue Shield Insurance Plans |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xmortality |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 |
_aGraft Rejection _xdrug therapy |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInsurance Coverage |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 |
_aPancreas Transplantation _xmethods |
| 650 | 0 | 4 | _aTechnology Assessment, Biomedical |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 773 | 0 |
_tTecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel _gp. 33-7 |
|
| 999 |
_c11838109 _d11838109 |
||